




February 2011

Volume 16 · Numbers 3/4

pp. 91–172



Cover Story

The leading story of this issue of *Drug Discovery Today*, by Graeme Horne, Francis X. Wilson, Jon Tinsley, David H. Williams and Richard Storer discusses the therapeutic value of what is possibly the most attractive class of carbohydrate mimetics, the iminosugars. They postulate that this class of molecule can take advantage of our developing understanding of the field of glycobiology and its influence on pathology and potential pharmacology. They highlight how the early attempts at developing drugs around these structures suffered from a lack of selectivity and resultant side-effects in the clinic; current approaches have improved potency and selectivity and, as a result, have a broader range of applications.

REVIEWS

KEYNOTE

107 Iminosugars past, present and future: medicines for tomorrow

Graeme Horne, Francis X. Wilson, Jon Tinsley, David H. Williams and Richard Storer

FOUNDATION REVIEW

119 Phenothiazine: the seven lives of pharmacology's first lead structure

Maïke J. Ohlow and Bernd Moosmann

GENE TO SCREEN

132 *In vitro* models for human skin disease

Lydia Semlin, Monika Schäfer-Korting, Claudia Borelli and Hans C. Korting

POST SCREEN

140 Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy

Erlong Zhang, Chao Zhang, Yongping Su, Tianmin Cheng and Chunmeng Shi

147 Outsourcing lead optimization: the eye of the storm

David E. Clark

158 Lead optimization in the nondrug-like space

Hongyu Zhao

164 The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types

Timothy J. Ritchie, Simon J.F. Macdonald, Robert J. Young and Stephen D. Pickett